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Background: The incidence of health care-acquired infection (HAI) and the consequence for patients with
HAI tend to vary from study to study. By including all patients, all medical specialties, and performing a
follow-up analysis, this study contributes to previous ﬁndings in this research ﬁeld.
Methods: Data from the Swedish National Point Prevalence Surveys of HAI 2010-2012 was merged with
cost per patient data from the county Health Care Register (N = 6,823). Extended length of stay (LOS) and
costs related to an HAI were adjusted for sex, age, intensive care unit use, and surgery.
Results: Patients with HAI (n = 732) had a larger proportion of readmissions compared with patients with
no HAI (29.0% vs 16.5%). Of the total bed days, 9.3% was considered to be excess days attributed to the
group of patients with an HAI. The excess LOS comprised 11.4% of the total costs (95% CI, 10.2-12.7). The
1-year overall mortality rate for patients with HAI in comparison to all other patients was 1.75 (95% CI,
1.45-2.11), all 5 of these differences were statistically signiﬁcant (P < .001).
Conclusions: Even if not all outcomes for patients with an HAI can be explained by the HAI itself, the
increase in inpatient days, readmissions, associated costs, and higher mortality rates are quite notable.
© 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier
Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
A health care-acquired infection (HAI) is deﬁned as an infec-
tion occurring during the process of care in a hospital or other health
care facility, neither present nor incubating at the time of admis-
sion nor at the time of a visit to a health care facility.1 HAIs are known
to comprise the largest part of adverse events in health care and
cause prolonged hospital length of stay (LOS) and deaths.1-4
In earlier studies, point prevalence surveys have been used to
provide information on the presence of HAIs, and costs have been
estimated indirectly from the extension of LOS and the mean cost
of hospital days in different specialties.4-6
Depending on the type of HAI and the mix of patients in-
cluded, previous studies have shown different results regarding LOS
resulting from HAI. Plowman et al7 found that HAIs in general ex-
tended the LOS by 14 days, which was almost 3 times longer than
the average LOS for patients without an HAI. There was a large vari-
ation in extended stay depending on the site of single infection (2-
13 days) and admission specialty (1-23 days).
Sheng et al8 found that the additional LOS was around 20 days
for patients affected by an HAI. They also addressed a diﬃculty re-
garding estimating costs for HAIs among inpatients by pointing out
a higher mortality rate among patients with an HAI than among
uninfected patients. Death reduces the direct medical costs but rep-
resents for each patient a unique loss of potential life years.
Klevens et al9 estimated a US case fatality rate of HAI in hospi-
talized patients to 5.7% during 1999-2002, with the highest mortality
rate in ventilator-associated pneumonia (14.4%) and catheter-
associated bloodstream infections (12.3%). In Europe the 30-day
mortality rate for Clostridium diﬃcile infection (CDI) is estimated to
be from 3%-30% in different countries.10 Kaye et al11 showed that
the 90-day mortality rate in hospitalized older adults rises from
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33.2%-49.4% (odds ratio, 2.1; P < .001) in patients with a health care-
associated bloodstream infection.
One challenge in estimating the effect of the additional LOS for
patients with an HAI is to extract the effect of the infection from
that of any other complications or disease progression. Regression
analysis with adjustment for patient characteristics has therefore
been a way to clear the effects of an HAI.4,7
Readmissions aremore common for patients with an HAI. Chopra
et al12 found that it was about twice as common that patients with
CDI had a readmission within 30 days compared with all other pa-
tients (30.1% vs 14.4%).
Aim
The aim of this study was to examine the effects of HAI by cal-
culating the difference in LOS and actual direct health care costs for
patients with an HAI compared with patients without HAI. Addi-
tional LOS and costs resulting from any ﬁrst hospital readmission
within 30 days from discharge were also included in the analysis,
as was the survival rate (as mortality ratio) between the 2 groups
1 year after the primary discharge.
MATERIALS AND METHODS
Setting
The County of Östergötland has the fourth largest population in
Sweden, with 434,000 residents and the Region Östergötland (for-
merly the County Council) both provides and is responsible for all
public health care in the county. All patient encounters, including
primary care, are registered in the Health Care Register (HCR). The
county has 3 hospitals, 1 of which is a university hospital.
The Point Prevalence Surveys of HAI
Directed by the Swedish Association of Local Authorities and
Regions (SALAR) and using the Swedish National Board of Health
andWelfare’s deﬁnition of HAI, the Point Prevalence Surveys of HAI
(PPS-HAI) have been conducted in the majority of public somatic
hospitals in Sweden every spring and fall since 2008 and around
20,000 patients are included each semester. The PPS-HAI was con-
ducted with national standard protocols and instructions by SALAR
andwas performed by nurses and attending physicians on eachward
during all somatic clinics. The team that makes the registrations
during the days the PPS is administered has to read and under-
stand the instructions (from SALAR) detailing how to perform the
survey.
All inpatients on a somatic ward on a given day were included.
Demographic data (age, identity, and sex) were recorded, as was in-
formation on medical specialty. HAI was deﬁned as an intention-
to-treat diagnosis or ﬁnal diagnosis of postoperative infection within
30 days from surgery or within 1 year if implantation surgery;
device-related infections due to central venous catheters, urinary
tract catheters, ventilator treatment, or endotracheal tubes or in-
dwelling cerebral ventricular drainage; drug-related infections
deﬁned as C diﬃcile enteritis, infections related to chemotherapy
for cancer, or infections due to other immune-modulating drugs or
corticosteroids; and other infections occurring > 48 hours after ad-
mission. The HAI was categorized according to the suspected
anatomic site of the infection origin.
The Point Prevalence Register
The Point Prevalence Register (PPR) used includes local data from
the County of Östergötland recorded in the national surveys for 2010-
2012, together with data from 4 extra surveys conducted in the same
way during 2012. The data encompass 10 separate prevalence mea-
surements with an average of 800 patients per registration (range,
729-829). Of all unique patients in this study, 58% were inpatients
at the university hospital. The registrations included nonresidents
in the county.
The validation of the national PPS for HAI in hospital care during
autumn 2012
On commission of SALAR, the ﬁrst author (MR) conducted a na-
tional validation study in 2013. The validation study design was to
let an independent team consisting of specialists in infectious dis-
eases do the same survey as the ordinary team on the same day.
The primary aim was to see how well the results correlated. The
study involved 1,216 patients across 20 hospitals in Sweden, the spe-
cialties chosen for the study were general surgery and internal
medicine. In total, the independent teams foundmore patients with
an HAI than the ordinary teams did (8.3% in the ordinary survey,
whereas the validation teams found a prevalence of 13.1%) (95% con-
ﬁdence interval [CI], 11.2-15.0) (Table B in the Supplementary
material). All registered cases of HAI became 15.3% when the ﬁgures
from the 2 independent registrations were added together (Table
A in the Supplementary material).
On the local level the validating teams found a higher preva-
lence at 17 hospitals, the same prevalence at 2 hospitals, and a lower
level at 1 hospital. The conclusion from the validation study was
that the ordinary teams inmost cases underestimated the true prev-
alence. Details of the validation study are provided as supplementary
material.
The HCR
Record data on medical specialty, main diagnosis, LOS, costs, and
other factors for each inpatient in somatic care were retrieved from
the HCR. All visit or hospitalization records include a personal iden-
tiﬁcation number (PID), date of visit or hospitalization, day of
discharge, and diagnosis according to ICD-10,13 with main diagno-
sis and secondary diagnosis. The patient-speciﬁc medical costs for
visits and inpatient care in the HCR were priced with the addition-
al module of cost per patient containing the diagnosis-related group
costs per patient, as described in other studies.14 The detailed cost
ﬁgures in the cost per patient module (ie, pricing) are adminis-
trated by SALAR.
There were 8,104 registrations with a valid PID in the PPR, but
59 of them were double registrations on the same PPS for patients
with >1 HAI, thus leaving 8,045 unique registrations. However, 27
of these cases were doubled for patients who had been registered
on >1 PPS during the same admission, leaving 8,018 unique pa-
tients to be matched with the HCR. When wemerged PPR data with
HCR data, 37 patients from the PPR were impossible to ﬁnd in the
HCR. For these cases, we suspect that an incorrect PID had been
entered in the PPR, and we found no systematic selection bias for
the 23 patients for whom we could ﬁnd no information. These 23
(of 37) patients were completely random across surveys andmedical
departments.
The complete and valid records resulted in 7,981 patients, of
whom 316 died during admission (Table 1). In the 30-day follow-
up of readmissions and in the calculation of 1-year survival after
the discharge of the PPS admission the study populationwas reduced
to 7,062 patients, of whom 6,823 were adults. Only residents of the
county who were registered in the HCR could be part of the follow-
up, and only patients who survived the original admission and the
30-day follow-up could be included in the ﬁnal analysis.
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Direct cost calculations
The costs are expressed in Euros, in the price level of 2012. The
costs for 2010 and 2011were inﬂatedwith the consumer price index
to reﬂect 2012 prices. The exchange rate from Swedish crowns (SEK)
to Euros was set to SEK 9 per Euro. To convert the costs to US dollars,
use a factor of 1.3 times the cost in Euros, derived from the monthly
averages of exchange SEK to US dollars during 2012, a year average
of SEK 6.8 per US dollar.
Study design
The ﬂow chart in Figure 1 illustrates how each patient can have
a unique date for admission, but share the PPS date with other pa-
tients for that particular survey. Ten independent surveys were
performed during the study period 2010-2012. Of 7,062 eligible pa-
tients 1,245 had 1 or more readmissions within 30 days from
discharge from the original admission. Only any ﬁrst readmission
within 30 days from discharge was included in the calculations of
total LOS and costs.
The prevalence rate of HAI in Table 2 was created by adding any
new cases of HAI that were registered with ICD-10 codes during
the readmission (n = 50), yielding a total of 740 patients with HAI
of whom 732 were adults. The mortality rate was calculated for a
period of 365 days, starting on the date of discharge from the orig-
inal admission. However, patients who died during the admission
or the follow-up period were excluded from the regression analy-
ses and the mortality rate calculations. Therefore, all patients in the
regression were alive 30 days after the discharge from the original
admission.
Statistical analysis
The χ2 test was used for comparing the prevalence of HAI and
gender differences of subgroups versus the total, and also for mor-
tality ratios of deaths during admission. Student t test was used for
average age comparison, whereas linear regression analysis was used
for the main outcome of the adjusted proportions for excess bed
days and direct medical costs. Any differences in 1-year survival were
tested with multinomial regression onmortality ratio, together with
standardized mortality ratio (SMR) based on the expected outcome
for the reference population who did not experience HAI. P
values < .050 were considered statistically signiﬁcant. All statistics
and dataset arrangements were done with IBM SPSS version 22 and
version 23 (IBM-SPSS Inc, Armonk, NY).
Regression analysis including 30-day readmission follow-up
In the follow-up analysis, LOS and cost per patient in all pa-
tients residing in the county eventually readmitted within 30 days
from discharge and alive during the follow-up period (n = 7,062),
were included. Nonresidents (n = 226) were excluded because of a
lack of data regarding continued hospital care and readmissions in
their home county. Only the ﬁrst readmission was included because
several patients had >1 readmission within 30 days. Data for the
Table 1
Number of patients in the dataset and test for health care-acquired infection (HAI) prevalence differences, by subgroup
Group n HAI, n HAI, %
P value for
HAI vs total
Mean
LOS
Median
LOS
Mean cost
€1,000
Unique registrations in PPR (1 PID/admission) found in the HCR 7,981 860 10.8 12.0 7 15.1
Men all ages 3,858 481 12.8 .006 12.8 7 17.9
Women all ages 4,123 379 9.2 −.003 11.2 7 12.5
Patients who died during the hospitalization (excluded) −316 55 17.4 <.001 20.6 15 28.3
Patients who died within 30 d after discharge (excluded) −341 54 15.8 .003 17.4 13 16.0
Patients with >90 days of hospitalization (excluded) −46 24 52.2 <.001 136.9 113 384.6
Nonresidents all ages discharged alive (excluded) −221 34 15.4 .037 12.4 7 25.3
Remaining patients for main analyses
Patients/residents in the follow-up with an LOS during PPS ≤ 90 d 7,062 697 9.9 ns 10.6 6 11.8
Children/residents aged 0-17 y alive >30 d from discharge 239 8 3.3 −<.001 6.4 4 9.8
Adult patients/residents alive >30 d from discharge 6,823 689 10.1 ns 10.7 7 11.9
Readmissions
All readmissions within 30 d from discharge 1,403 198 14.1 <.001 13.6 8 15.7
Valid readmissions within 30 d from discharge (alive and resident) 1,257 177 14.1 <.001 13.4 8 15.9
HCR, Health Care Registry; LOS, length of stay; ns, not signiﬁcant; PID, personal identiﬁcation number; PPS, point prevalence survey; PPR, Point Prevalence Register.
Fig 1. The study design illustrated in a ﬂow chart for admissions, how health care-acquired infections (HAIs) are registered, and when survival status is checked. Survival
status is checked 365 days from the discharge date of the ﬁrst and original admission. LOS, length of stay; PPS, Point Prevalence Survey.
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adult patients were stratiﬁed by medical specialty (Table 2 and
Table 3).
Group of HAI and the proportion of excess bed days
The 4 main types of HAI registered in the PPS were postsurgery
infection, other invasive procedure-related infections,
pharmaceutical-related infections, and other infections (Table 4).
The proportion of excess bed days for these groups were analyzed
in the same manner as across specialty.
The 1-year mortality rate test
The HCR is linked to the vital statistics for the county popula-
tion and for the patients who died within 1 year from the original
admission discharge the date information was entered to the mor-
tality rate analysis. The SMR is presented together with 2 nominal
regressions of the 1-year survival (mortality ratio), ﬁrst with age
and sex as adjusting factors, followed by a second analysis where
any presence of intensive care unit stay or surgery also were added
into the regression as adjusting factors for survival.
Ethics approval
This study was approved by the Regional Ethics Committee at
Linköping University, Sweden (2013/196-31).
RESULTS
The average prevalence of HAI for all patients (N = 7,981) was
10.8%. For patients in the main analyses (n = 7,062) the prevalence
of HAI in the PPS was 9.9%. For this group of patients and resi-
dents there was a variation of prevalence of HAI in the 10
independent PPSs between 8.7% and 13.1%, with an average of 9.9%.
Of the total patient population in somatic care there were fewermen
compared with women (48.3% vs 51.7%; P = .008). However, the pro-
portion of menwas greater in the following groups (P < .01): patients
with >90 days hospitalization (76%), children alive >30 days from
Table 2
Total bed days and percent excess days related to patients with a health care-acquired infection (HAI)
n HAI, n HAI, %
Number of days
Percent of days for
the group with HAI
Adjusted portion of excess days for
the group with HAI,* %
Total
For all
Group
HAI Total
Unadjusted
excess HAI
Adjusted
%
95% Conﬁdence
interval P value
All patients of all ages with a Point Prevalence
Survey admission
7,062 740 10.5 74,657 14,517 19.4 10.0 9.1 10.0-12.9 <.001
All patients all ages with any ﬁrst readmission 7,062 740 10.5 83,838 16,762 20.0 10.6 9.4 11.1-13.9 <.001
Children/residents aged 0-17 y 239 8 3.3 1,692 188 11.1 8.0 7.0 2.8-14.6 .004
Adult patients aged 18 y and older
All adult patients 6,823 732 10.7 82,146 16,574 20.2 10.6 9.3 8.4-10.2 <.001
Ear, nose, and throat 116 9 7.8 881 216 24.5 18.2 17.5 11.4-23.5 <.001
Gynecology 498 22 4.4 2,600 292 11.2 7.1 6.2 3.6-8.6 <.001
Infection 283 58 20.5 4,930 1,356 27.5 8.8 7.9 2.5-13.4 .005
Internal medicine 3,344 324 9.7 45,904 7,764 16.9 8.0 7.6 6.5-8.8 <.001
Orthopedics 906 87 9.6 8,523 1,986 23.3 11.9 12.3 10.0-14.5 <.001
Surgery 1,414 189 13.4 17,031 4,502 26.4 15.1 12.3 10.3-14.5 <.001
Urology 262 43 16.4 2,547 728 28.6 14.5 13.2 6.9-19.6 <.001
Patients without intensive care unit stay 6,315 617 9.8 71,238 12,845 18.0 7.0 8.8 7.9-9.8 <.001
Patients with intensive care unit stay 508 115 22.6 10,907 3,727 34.2 12.2 13.5 9.8-17.3 <.001
Patients without surgery 6,046 562 9.3 65,701 11,355 17.3 7.4 8.8 7.8-9.6 <.001
Patients with surgery 777 170 21.9 16,445 5,198 31.6 10.8 11.7 8.6-14.7 <.001
*Excess costs adjusted for sex, age, intensive care unit use, and surgery.
Table 3
Total costs and percent excess costs related to patients with a health care-acquired infection (HAI)
No HAI, n HAI, n HAI, %
Costs in €1,000
Percent of costs for
the group with HAI
Adjusted portion of excess costs for
the group with HAI,* %
Total
for all
Group
HAI Total
Unadjusted
excess HAI
Adjusted
%
95% Conﬁdence
interval P value
All patients of all ages with a Point Prevalence
Survey admission
6,322 740 10.5 83,570 18,648 22.3 13.2 10.3 8.9-11.5 <.001
All patients of all ages with any ﬁrst readmission 6,322 740 10.5 95,979 21,760 22.7 13.6 10.9 9.7-12.2 <.001
Children/residents aged 0-17 y 231 8 3.3 2,805 249 8.9 5.7 5.2 1.7-8.8 .004
Adult patients aged 18 y and older 0
All adult patients 6,091 732 10.7 93,175 21,511 23.1 13.8 11.4 10.2-12.7 <.001
Ear, nose, and throat 107 9 7.8 1,083 178 16.8 9.5 8.7 1.7-15.9 .016
Gynecology 476 22 4.4 2,549 380 14.9 11.0 9.8 7.5-12.0 <.001
Infection 225 58 20.5 4,823 1,570 32.6 15.2 13.7 6.2-21.1 <.001
Internal medicine 3,020 324 9.7 44,984 8,482 18.9 10.2 9.5 7.7-11.2 <.001
Orthopedics 819 87 9.6 8,519 1,430 16.8 8.0 7.9 4.6-11.3 <.001
Surgery 1,225 189 13.4 28,499 8,690 30.5 19.8 15.2 12.7-17.9 <.001
Urology 219 43 16.4 2,714 776 28.6 14.6 13.7 5.2-22.2 .002
Patients without intensive care unit stay 5,698 617 9.8 68,899 13,022 18.9 10.1 9.5 8.2-10.6 <.001
Patients with intensive care unit stay 393 115 22.6 24,275 8,488 34.7 15.9 26.5 18.5-34.5 <.001
Patients without surgery 5,484 562 9.3 61,670 10,818 17.5 9.1 9.0 7.8-10.3 <.001
Patients with surgery 607 170 21.9 31,504 10,693 33.9 15.4 24.0 17.8-30.2 <.001
*Excess costs adjusted for sex, age, intensive care unit use, and surgery.
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discharge (58%), and in the group that had at least 1 readmission
within 30 days from discharge (53%).
Men had a signiﬁcantly higher prevalence of HAI than women
(Table 1). Patients who died during the hospitalization or within
the 30-day follow-up had a higher prevalence of HAI than average
(17.4% and 15.8%, respectively). Children had a lower prevalence of
HAI (4.3%), whereas nonresidents had a higher prevalence of HAI
than average (15.2%) (Table 1). During the admission 6.4% of pa-
tients with an HAI died compared with 4.4% of the other patients,
which was a statistically signiﬁcant difference according to Mantel-
Haenzel test (χ2 = 6.6; P = .005).
Of 7,062 patients/residents alive during the 30-day follow-up
period, 1,245 had a readmission within 30 days. Patients with HAI
(n = 732) had a larger proportion of readmissions compared with
patients with no HAI (29.0% vs 16.5%). Half of all readmissions (49.6%)
were admitted within 10 days of discharge. Of the readmitted pa-
tients, 43 new patients received a diagnosis that explicitly indicated
they experienced an HAI that was not registered in the PPS. Within
the top-10 reasons for a readmission, we noted the following 4 ICD-
10 groups, each group to a varying extent related to a previous care
episode: T81.4 “Infection following a procedure, not elsewhere clas-
siﬁed”; T81.8 “Other complications of procedures, not elsewhere
classiﬁed”; A04.7 “Enterocolitis due to Clostridium diﬃcile”; and J18.9
“Pneumonia, unspeciﬁed.” The top-10 diagnoses accounted for 17.9%
of all readmitted cases. It was almost twice as common that pa-
tients with a registered HAI had a readmission (29.2%) compared
with other patients (16.3%) (n = 216 and n = 1,029, respectively).
The results in adjusted LOS and excessive costs for adult pa-
tients are presented by specialty and subgroup as percentage of the
total bed days and costs. Adjustment for age, sex, intensive care unit
use, and surgery was done for several reasons: patients with an HAI
were older than patients without an HAI (P = .001), men had a sig-
niﬁcantly higher prevalence of HAI (P < .001), the prevalence of HAI
was signiﬁcantly higher among patients who had received inten-
sive care, and the group with surgery had a statistically signiﬁcantly
higher prevalence of HAI than the group without surgery (P < .001)
(Table 1). For adult patients (n = 6,823) (see Table 2 and Table 3) a
total of 7.4% had a period of intensive care unit use, and a total of
11.4% underwent surgery.
In the follow-up analysis including readmission (n = 6,832), the
prevalence of HAI among adult patients was 10.7% (n = 732). The
total number of bed days for adult patients without an HAI com-
prised 79.8% of all bed days, and patients with an HAI accounted
for 20.2% of all days. Of all days, 9.3% were considered to be excess
days for the group with an HAI (Table 2) and the adjusted average
of excess days were 10.5 per patient with an HAI (95% CI, 9.5-
11.5). The cost for the excess days was, after adjustment, 11.4% of
the total costs (95% CI, 10.2-12.7) (Table 3). The difference across
medical specialties was large, ranging from 6.2% of the subtotal days
(infection speciality) to 17.5% of the subtotal days (ear, nose, and
throat specialty) (Table 2). The share of excessive costs compared
with the subtotal costs for patients with HAI varied between 7.9%
(orthopedics specialty) and 26.5% (surgery specialty) (Table 3).
The analyses of the 4 main types of HAI show that patients with
infections related to pharmaceutical treatment were the group that
added most to the proportion of adjusted excess bed days (2.7%),
despite the fact that this group was the smallest of the 4
groups (Table 4).
The 1-year survival was calculated from the day of discharge from
the ﬁrst admission (the admission when the PPS was completed) for
patients whowere alive during the admission and the 30-day follow-
up. One year fromdischarge, 15.2% of patientswhohadnoHAI haddied
comparedwith 24.5% of patientswith anHAI. This gave an SMRof 1.61
(95% CI, 1.39-1.86; P < .001) (Fig 2). The nominal regression for 1-year
survival gave an adjusted mortality ratio of 1.75 for patients with HAI
comparedwith other patients, whichwas statistically signiﬁcant with
a P value <.001 (95% CI, 1.45-2.11). This regressionwas adjusted for age
and sex, but in the extended nominal regression intensive care unit stay
and surgerywas also adjusted for. Including intensive care and surgery
into the regression slightly increased the mortality ratio for patients
with an HAI to 1.81 (95% CI, 1.50-2.19).
DISCUSSION
Adult patients registered with an HAI encompassed about a 10th
of all admitted patients in our study. However, the PPS-HAI ﬁgure
is not the true prevalence of HAI, but shows the proportion of hos-
pital beds occupied by patients with an HAI during a given day. To
include all patients in a hospital during 1 day, as done in a PPS, favors
patients with long hospital stays, whereas a representative sample
would not. Despite this length bias we consider the patients with
or without a HAI in this study as 2 comparable groups. Thereby any
differences in the outcomes shall be regarded as true differences,
but LOS and costs are not representative of the whole patient pop-
ulation. The criteria for inclusion in the analyses (ie, excluding
children, patients who had a LOS > 90 days, and patients who died
before the 30-day follow-up period ended) also contributes to re-
ducing the generalizability to a complete patient population. Some
of these exclusions reduce the inﬂuence from outliers who have ex-
traordinary long treatment periods and associated extreme costs.
And by concentrating on adult patients, we excluded outliers with
more than 3 months’ LOS, and also only include patients who sur-
vived the admission and the following month, we believe that we
to some degree deﬂate the overall effects of HAI, and also increase
the generalizability to other studies that will use the same design.
The use of intention-to-treat diagnoses supplemented with ICD-
10 diagnoses indicating HAI probably increases the incidence of HAI,
unlike the use of well-deﬁned ﬁnal diagnoses,15 although the use
of ﬁnal diagnoses could be criticized for underestimating the number
of patients with HAI and thereby the costs.
In the follow-up analysis with any ﬁrst readmission, we found
that the total number of bed days increased with 14.2% for the group
Table 4
Total bed days and percent excess days related to patients with a health care-acquired infection (HAI) across type of HAI
Adult patients aged 18 y and older n HAI, n HAI, %
Number of
bed days
Percent of days for
the group with HAI
Adjusted portion of excess days for
the group with HAI,* %
Total
Group
HAI Total
Unadjusted
excess HAI Adj. %
95% Conﬁdence
interval P value
Postsurgery infection 6,823 225 3.3 82,146 4,917 6.0 3.1 2.4 2.1-3.0 <.001
Other invasive procedure-related infections 6,823 185 2.7 82,146 3,969 4.8 2.4 2.0 1.5-2.4 <.001
Pharmaceutical-related infection 6,823 158 2.3 82,146 3,908 4.8 2.7 2.7 2.3-3.1 <.001
Other infections 6,823 164 2.4 82,146 3,780 4.6 2.5 2.3 1.9-2.6 <.001
Total 6,823 732 10.6 82,146 16,574 20.2 10.7 9.3 8.4-10.2 <.001
*Excess costs adjusted for sex, age, intensive care unit use, and surgery.
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with a HAI compared with 11.5% for the group without any HAI. To
include readmission is a rather new and a most-relevant ap-
proach in this research ﬁeld, because an HAI may ﬁrst become
observable after discharge. By including readmissions, a more com-
plete picture of patient-related LOS and costs can be achieved. Just
like Chopra et al12 in their study regarding CDI, we found that it was
about twice as common that patients with an HAI had a readmis-
sionwithin 30 days comparedwith all other patients, which conﬁrms
the relevance of adding the LOS and costs for any ﬁrst readmis-
sion (or several readmissions) when studying the effects of HAI.
The signiﬁcant increase of inpatient days following an HAI that
we found is in line with previous studies7,8,16; however, we avoided
counting days per patient in favor of group statistics. One great chal-
lenge when estimating the effect of LOS for patients with an HAI
is to extract the effect of the infection and not exaggerate the LOS
from any other complications or disease progression. A straight-
matched, case-control study can reduce the effects of confounding
factors, and DiGiovine et al17 present a good example where sever-
ity of illness was accounted for, and they found that the excess LOS
was 10 days for patients with primary nosocomial bloodstream in-
fections. The approach of Vrijens et al18 to the problem was both
to concentrate on 1 type of HAI—bloodstream infection—and to study
the outcome on a matched cohort. The adjusted mean difference
in LOS between infected and uninfected patients was reduced by
about 20% when matched for primary diagnosis and comorbidity.
We had no such sophisticated data, but made adjustments for age,
sex, intensive care unit use, and surgical operations, which signiﬁ-
cantly reduced the average difference on the total level. To include
more background factors and risk factors would reduce the differ-
ences between the groups, but such an inclusion would on the other
hand make the interpretation of the outcomes more diﬃcult.
Comorbidity might contribute to a longer hospital stay for a
patient with an HAI (above average for patients with an HAI with
no comorbidity) but if the patient with comorbidity was not af-
fected by an HAI in the ﬁrst place, then the hospital stay would have
been shorter, at best the average length for patients without any
HAI. The differences between infected and uninfected patients in
this study do not show a pure effect of the HAI. Although, as could
be seen in the validation study, prevalence rates are often under-
estimated in the majority of the Swedish PPS for HAI, and if there
were more infected patients in our data, the percentage of days and
costs would increase.
Including ﬁgures for readmission and overall mortality up to 12
months from discharge gives this study a rather complete and unique
picture of the patients registered in the initial prevalence surveys.
Most studies that report mortality, more than in-hospital mortal-
ity, use a 30-day period and of 56 studies that reported mortality
for patients with CDI, only 4 studies followed their patients for 12
months,10 indicating that 12-monthmortality ﬁgures are rare because
in the same systematic review 14 studies had ﬁgures only for 30-
day mortality, whereas the 38 remaining studies had ﬁgures for in-
hospital mortality and/or mortality up to 60 or 90 days. According
to the same inﬂuence that risk factors and comorbidity have on the
outcomes of reduced number of days and costs, the difference in
mortality rate presented in this study would decrease signiﬁ-
cantly if patient risk factors was entered into the survival regression.
Unfortunately we lack information concerning relevant factors such
as comorbidity, health status, body weight, and lifestyles.
Considering that Harbarth et al19 estimated the percentage of all
preventable HAIs at about 15%, and that Lambert et al20 suggested
that for speciﬁc HAIs such as ventilator-associated pneumonia and
bloodstream infections in ICUs 52% and 69%, respectively, are pre-
ventable, there is often a potential to reduce the occurrence of HAI.
In that light, our results imply that a reduction of HAI prevalence
to a signiﬁcant degree could reduce health care costs, lessen patient
suffering, and also increase patients’ long-term survival.
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Fig 2. One-year survival rate from the primary discharge (%) for adult patients who survived the 30-day follow-up period. Patients who had a primary length of stay of
>90 days are excluded. HAI, health care-acquired infection.
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